Navigation Links
The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
Date:2/26/2009

lty payments totaling $1.1 million to The Quigley Corporation over the time period. If minimum payments and terms are not met within the five year period, Quigley retains full rights and ownership of the property, however, Levlad can continue to pay per unit royalties beyond five years for a non-exclusive license.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration.

Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing In
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
2. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
3. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
4. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
5. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
6. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
7. Service Corporation International Announces Fourth Quarter 2008 Financial Results and Comments on Outlook for 2009
8. Heyltex Corporation to Become Exclusive Distributor of ThyroShield(R)
9. CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application
10. Providence Service Corporation Announces Bylaw Amendments to Improve Corporate Governance
11. Service Corporation International Announces Schedule for Its Fourth Quarter 2008 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... BrainHealth will bring together national experts to discuss ... its inaugural Brain Health Summit, titled "The Human ... include Dr. Sandra Bond Chapman, founder and chief ... Chuck Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) ... and Early Learning, U.S. Department of Education. The ...
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... CORVALLIS, Ore. An Oregon State University researcher has ... severity of the symptoms of autism spectrum disorder in ... the be the first to show a direct relationship ... of fine and gross motor skills should be included ... Megan MacDonald, an assistant professor in OSU,s College of ...
(Date:4/24/2014)... a scientist at the University of York reveals that ... development of the nervous system may also play a ... A research team, led by Dr Will Brackenbury, a ... at York, has studied how voltage-gated sodium channels assist ... found in the membranes of excitable cells, such as ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... , , ... Corp., the leader in clinically proven brain fitness software, and ... collaboration to empower individuals with knowledge and tools that can ... this first-of-its-kind offer, consumers will have the opportunity to complement ...
... , , HOUSTON, Sept. ... that Dan Moore, President and Chief Executive Officer, and Greg Browne, ... Conference in New York on Tuesday, September 22, 2009 at 4:00 ... live and by replay at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=82_IT8KY1C . ...
... , PORTLAND, Maine, Sept. 10 ... Council for Disability Awareness (CDA) reveals a surge in the number ... , , The CDA,s 4(th) Annual Long-Term Disability ... identifies continuing and emerging disability trends among U.S. workers. Fifteen CDA ...
... STERIS Corporation (NYSE: STE ) today announced that the ... in New York on Tuesday, September 22, 2009. Michael J. ... p.m., Eastern time. , , The presentation can ... at www.steris-ir.com . The presentation will be ...
... ... Pioneer in the Development of Telehealth-Supported Solutions for Connected Care , ... Minneapolis, MN (PRWEB) September 10, 2009 ... Lenzmeier as chairman. Founded in 1993, ATI is the pioneer in the development and ...
... , , ANN ... biopharmaceutical company, today announced positive efficacy results from the second ... study for Ophena(TM) (ospemifene tablets), the company,s investigational ... (VVA). This study, together with the recent completion of ...
Cached Medicine News:Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 2Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 3Health News:Cyberonics to Present at UBS Global Life Sciences Conference 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 3Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 2Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 3Health News:Allen Lenzmeier Elected Chairman of the Board of Directors of American TeleCare, Inc. (ATI) 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 3Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 4
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... (Nasdaq: SLTM ), a global leader in the ... the Tenth Annual JMP Securities Research Conference at the Ritz-Carlton ... pm Pacific Time. Stephen J. Fanning, Chairman, President and Chief ... corporate events. Attendance at this conference is by ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) ... medical devices to biopharmaceutical and healthcare organizations and ... efficacy services in drug development, announced today results ...  Unless otherwise noted, all comparative numbers refer to ...
Cached Medicine Technology:Solta Medical to Present at the JMP Securities Research Conference 2ERT Reports First Quarter 2011 Operating Results 2ERT Reports First Quarter 2011 Operating Results 3ERT Reports First Quarter 2011 Operating Results 4ERT Reports First Quarter 2011 Operating Results 5ERT Reports First Quarter 2011 Operating Results 6ERT Reports First Quarter 2011 Operating Results 7ERT Reports First Quarter 2011 Operating Results 8ERT Reports First Quarter 2011 Operating Results 9ERT Reports First Quarter 2011 Operating Results 10ERT Reports First Quarter 2011 Operating Results 11
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: